Boulevard Bio Launches with $65 Million from Deerfield and World-Class Founders to Advance Precision Immunology Pipeline

Positive

AI Analysis

Summary

Boulevard Bio launched with $65 million in funding from Deerfield Management to advance a precision immunology pipeline. The company was founded by leading immunology and rheumatology experts including Prof. Georg Schett and Frank Nestle.

Importance:5/10

Sentiment:

0.70

company launchfundingprecision immunologyrheumatologyB cell biologyearly stage

Related Companies

$DTIL $WHEN

Read the original article

Published by PR Newswire Biotech on August 12, 2026 10:30 AM

Read Original